Skip to main content
ClaudeWave
Skill1.4k estrellas del repoactualizado today

tooluniverse-admet-prediction

This Claude Code skill performs comprehensive drug candidate profiling by integrating multiple ADMET prediction methods, including AI-based models, rule-based filters like Lipinski's rule-of-five, and experimental toxicity data from PubChemTox and ChEMBL databases. Use it to assess drug-likeness, blood-brain barrier penetration, bioavailability, hepatotoxicity risk, cytochrome P450 interactions, and oral absorption before committing compounds to laboratory testing or during early-stage compound library screening.

Instalar en Claude Code
Copiar
git clone --depth 1 https://github.com/mims-harvard/ToolUniverse /tmp/tooluniverse-admet-prediction && cp -r /tmp/tooluniverse-admet-prediction/plugin/skills/tooluniverse-admet-prediction ~/.claude/skills/tooluniverse-admet-prediction
Después abre una sesión nueva de Claude Code; el skill carga automáticamente.

SKILL.md

# ADMET Prediction & Drug Candidate Profiling

**ADMET reasoning**: a drug fails if it can't be absorbed, distributes to wrong tissues, isn't metabolized safely, or isn't excreted. Evaluate each property independently — good absorption doesn't compensate for liver toxicity. The ADME properties determine whether a compound reaches its target at therapeutic concentrations; toxicity determines whether it's safe to do so. Prioritize experimental data (T2) over computational predictions (T3) — ADMETAI predictions are screening tools, not definitive verdicts. When a FAIL is flagged in any toxicity category (hERG, AMES, DILI), treat it as program-limiting until wet-lab data refutes it.

**LOOK UP DON'T GUESS**: never assume SMILES, CID, or experimental LD50 values — always call PubChem to resolve compound identity before any ADMETAI or PubChemTox call.

Comprehensive pharmacokinetic and toxicity profiling integrating AI-based ADMET predictions, rule-based drug-likeness filters, and experimental benchmarks from curated databases.

## When to Use This Skill

**Triggers**:
- "What are the ADMET properties of [compound]?"
- "Is [drug] likely to cross the blood-brain barrier?"
- "Predict the toxicity of this SMILES: ..."
- "Does [compound] violate Lipinski's rule of five?"
- "Assess the drug-likeness of [molecule]"
- "What are the CYP interactions for [drug]?"
- "Pharmacokinetic profile of [compound]"
- "Is [compound] orally bioavailable?"
- "What is the LD50 / hERG liability of [molecule]?"

**Input**: Drug name (e.g., "ibuprofen") OR SMILES string (e.g., "CC(C)Cc1ccc(cc1)C(C)C(=O)O")

---

## COMPUTE, DON'T DESCRIBE
When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.

## KEY PRINCIPLES

1. **Resolve identity first** - Always convert drug name to SMILES before calling ADMETAI tools
2. **ADMETAI tools require `tooluniverse[ml]`** - If import fails, skip to SwissADME/PubChemTox fallbacks
3. **All ADMETAI tools take `smiles: list[str]`** - Always wrap in a list, even for one compound
4. **SwissADME takes `smiles: str`** - Single string, NOT a list (SOAP-style with `operation` param)
5. **PubChemTox tools accept `cid` or `compound_name`** - Use CID when available for reliability
6. **Evidence grading mandatory** - Predictions (T3), experimental data (T2), regulatory (T1)
7. **Scorecard output** - Every analysis must end with a pass/warn/fail scorecard
8. **Explain significance** - State WHY each property matters for drug development

---

## Evidence Grading

| Tier | Label | Source |
|------|-------|--------|
| **T1** | Regulatory/Clinical | FDA labels, ChEMBL max clinical phase |
| **T2** | Experimental | PubChemTox LD50/LC50, in vitro AMES, animal studies |
| **T3** | Computational | ADMETAI predictions, SwissADME calculations |
| **T4** | Annotation | Database cross-references, text-mined |

## Workflow: 5-Phase ADMET Profiling

```
User Query (drug name or SMILES)
|
+-- PHASE 1: Compound Identity Resolution
|   PubChem name->CID->SMILES, or validate input SMILES
|
+-- PHASE 2: Physicochemical & Drug-Likeness
|   ADMETAI physicochemical + SwissADME druglikeness -> Lipinski/Veber
|
+-- PHASE 3: ADME Predictions
|   BBB, bioavailability, CYP interactions, clearance, solubility
|
+-- PHASE 4: Toxicity Assessment
|   ADMETAI tox + PubChemTox experimental + nuclear receptor + stress
|
+-- PHASE 5: Scorecard & Clinical Context
|   ChEMBL max phase, aggregate pass/warn/fail, final recommendation
```

---

### PHASE 1: Compound Identity Resolution

**Goal**: Obtain SMILES, PubChem CID, and basic identifiers for the query compound.

**Steps**:

1. **If input is a drug name**:
   - Call `PubChem_get_CID_by_compound_name(name=<drug_name>)` to get CID
   - Call `PubChem_get_compound_properties_by_CID(cid=<CID>)` to get SMILES and MW
   - Extract `ConnectivitySMILES` from the response (NOT `CanonicalSMILES`)

2. **If input is a SMILES string**:
   - Call `PubChem_get_CID_by_SMILES(smiles=<SMILES>)` to get CID
   - Call `PubChem_get_compound_properties_by_CID(cid=<CID>)` for compound name and MW
   - Use the input SMILES for all subsequent ADMETAI calls

3. **Record**:
   - Compound name, CID, SMILES, molecular formula, molecular weight, IUPAC name
   - If CID lookup fails, proceed with SMILES only (ADMETAI does not need CID)

**Why this matters**: ADMETAI tools require SMILES input. PubChemTox tools work best with CID. Resolving both ensures all downstream tools can be called. PubChem is the authoritative source for SMILES canonicalization.

**Fallback**: If PubChem has no entry, the user must provide SMILES directly. Cannot proceed without SMILES.

---

### PHASE 2: Physicochemical Properties & Drug-Likeness

**Goal**: Evaluate whether the compound has drug-like physicochemical properties.

**Steps**:

1. **ADMETAI physicochemical** (primary):
   ```
   ADMETAI_predict_physicochemical_properties(smiles=["<SMILES>"])
   ```
   Returns: MW, logP, TPSA, HBD, HBA, rotatable bonds

2. **SwissADME drug-likeness** (complementary):
   ```
   SwissADME_check_druglikeness(operation="check_druglikeness", smiles="<SMILES>")
   SwissADME_calculate_adme(operation="calculate_adme", smiles="<SMILES>")
   ```
   Returns: Lipinski, Veber, Ghose, Egan, Muegge rule compliance; PAINS alerts; Brenk alerts

3. **ADMETAI solubility**:
   ```
   ADMETAI_predict_solubility_lipophilicity_hydration(smiles=["<SMILES>"])
   ```
   Returns: Aqueous solubility (LogS), lipophilicity, hydration free energy

**Interpret & Score**:

| Property | Ideal Range | Why It Matters |
|----------|-------------|----------------|
| MW | < 500 Da | Larger molecules have poor membrane permeability (Lipinski) |
| LogP | -0.4 to 5.6 | Too hydrophobic = poor solubility; too hydrophilic = poor permeability |
| HB
setup-tooluniverseSkill

Install and configure ToolUniverse for any use case — MCP server (chat-based), CLI (command line with 9 subcommands), or Python SDK (Coding API with 3 calling patterns). Covers uv/uvx setup, MCP configuration for 12+ AI clients (Cursor, Claude Desktop, Windsurf, VS Code, Codex, Gemini CLI, Trae, Cline, etc.), full CLI reference (tu list/grep/find/info/run/test/status/build/serve), Coding API quickstart, agentic tools, code executor, API key walkthrough, skill installation, and upgrading. Use when user asks how to set up ToolUniverse, which access mode to use (MCP vs CLI vs SDK), configuring MCP servers, using the CLI, troubleshooting installation, upgrading, or mentions installing ToolUniverse or setting up scientific tools. Also triggers for "how do I use ToolUniverse", "what's the best way to access tools", "command line", "tu command", "coding API", "tu build".

tooluniverse-acmg-variant-classificationSkill

Systematic ACMG/AMP germline variant classification with all 28 criteria (PVS1, PS1-4, PM1-6, PP1-5, BA1, BS1-4, BP1-7) for clinical significance. Produces 5-tier verdict (Pathogenic / Likely Pathogenic / VUS / Likely Benign / Benign) with cited evidence per criterion. Use for variant interpretation, VUS resolution, and pathogenicity assessment. Combines ClinVar, gnomAD, computational predictors, and gene-mechanism context.

tooluniverse-adverse-event-detectionSkill

Detect and analyze adverse drug event signals using FDA FAERS reports, drug labels, and disproportionality statistics (PRR, ROR, IC). Generates quantitative safety signal scores (0-100) with evidence grading. Use for post-market surveillance, pharmacovigilance, drug safety assessment, regulatory submissions, and detecting rare AE signals not visible in clinical trials.

tooluniverse-adverse-outcome-pathwaySkill

Map environmental and industrial chemicals to adverse outcome pathways (AOPs) — molecular initiating event to organ-level toxicity. Uses AOPWiki, GHS classification, IARC carcinogen status, and LD50 data. Use for environmental/industrial chemical risk assessment, regulatory-grade hazard characterization, and AOP stressor mapping. Distinct from drug-safety analysis (use tooluniverse-pharmacovigilance for drugs).

tooluniverse-aging-senescenceSkill

Aging biology, cellular senescence, and longevity research. Covers senescence markers (p16/CDKN2A, SASP, SA-beta-gal), aging hallmarks, senolytic drug discovery (dasatinib+quercetin, fisetin, navitoclax), epigenetic clocks, telomere biology, and longevity GWAS. Use for senescence-pathway analysis, age-related disease genetics, senolytic-target discovery, and centenarian-genetics queries. Distinguishes correlative vs causal evidence (knockout, intervention).

tooluniverse-antibody-engineeringSkill

Therapeutic antibody engineering and optimization, lead-to-clinical-candidate. Covers sequence humanization (germline alignment, framework retention), affinity maturation, developability (aggregation, stability, PTMs), structure modeling (AlphaFold/PDB CDR analysis), immunogenicity prediction, and manufacturing feasibility. Use for biologic-drug optimization, mAb design review, biosimilar engineering, and clinical-precedent comparison.

tooluniverse-binder-discoverySkill

Discover novel small-molecule binders for protein targets using structure-based and ligand-based screening. Covers druggability assessment, known-ligand mining (ChEMBL, BindingDB), similarity expansion, ADMET filtering, and synthesis feasibility. Use for hit identification, virtual screening, target-to-compounds workflows, and lead-finding before commit-to-medchem.

tooluniverse-cancer-classificationSkill

Translate free-text tumor descriptions to OncoTree codes and resolve cancer subtypes/tissue hierarchy. Cross-references UMLS/NCI vocabularies. Use for standardizing cancer-type nomenclature in EHR free-text, building cohorts in OncoKB or GDC, mapping tumor-board notes to ontology codes, and ensuring consistent terminology across cancer-genomics pipelines.